Skip to contentR
Relay Therapeutics, Inc.
R
RLAYRelay Therapeutics, Inc. Q2 2024 · 10-Q
Revenue$0.00$0.00−100.0% vs Q2 2023 Net Income-$92.21M-$92.21MN/M vs Q2 2023 EPS Diluted-$0.69-$0.69N/M vs Q2 2023 Operating Income-$100,757,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Relay Therapeutics, Inc. · CIK 1812364 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$65,844,000N/M ended Jun 30, 2024 · filed Aug 6, 2024 · 37 d after period end